Low-solubility and poorly bioavailable compounds pose persistent challenges in pharmaceutical pipelines. This webinar delves into Lonza's ‘right first time’ strategy, utilizing material-sparing and time-saving methods to swiftly advance molecules from development to commercialization.
Key aspects include:
- Feasibility screening to determine the optimal manufacturing approach between spray drying (SD) and hot melt extrusion (HME).
- Lonza’s innovative approach to screening HMEs, specifically at a milligram scale, to better capture the physical process of extrusion.
- Progression in amorphous solid dispersion (ASD) development from drug product intermediate to the final product, emphasizing material-sparing tools for formulation selection and scale-up.
The second part of the webinar focuses on efficient practices in ASD-based tablet feasibility and demonstration batches. It explores:
- Understanding key differences between spray drying and hot melt extrusion through feasibility screening.
- Material-sparing uses of a compaction simulator to inform tablet development.
- The significance of material-sparing techniques in saving time and costs during the scaling process.